Critical issues in drug and biomarker development

Bookmark and Share
Published: 2 Nov 2020
Views: 190
Prof Tracy Lively - National Cancer Institute, USA

Dr Tracy Lively speaks to ecancer about the critical issues in drug and biomarker development, which were discussed at the virtual IBCD 2020. 
She first explains what these critical issues are and then talks about the important points that must be kept in mind whilst designing and running bio-marker driven clinical trials.

Dr Lively points out several ways in which the critical issues regarding drug and biomarker development can be overcome. In the end, she gives her perspective of what the future looks like for drug and biomarker development.